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Abstract
Introduction: Echocardiography is a simple and established method of evaluating cardiac functions, assessing left ventricle geometry, and systolic 
and diastolic functions. Patients with chronic kidney disease have a tremendous burden of cardiovascular disease (CVD), and patients with end-
stage renal disease (ESRD) are at a greater risk of CVD and deaths. 
Materials and Methods: In this study, 245 incident dialysis patients were included, and none of the patient was on erythropoietin. All the patients 
were aged >18 years. Patients with ESRD, already on maintenance dialysis, were not included in this study. Patient’s data such as demographic 
details, comorbidities, laboratory values, echocardiographic changes, management, and outcome were recorded. 
Results: Out of 245 patients, 165 (67.3%) were males and 80 (32.6%) females. The mean age of the patients was 49.7 years. Left ventricular 
hypertrophy (LVH) was observed in 188 (76.7%), mild left ventricular dysfunction (LVD) in 25.7%, moderate LVD in 23.67%, severe LVD in 
8.5%, global hypokinesia in 33.8%, valvular heart disease in 26.5%, regional wall motion abnormality in 4.4%, and pericardial effusion in 1.6% 
patients. Echocardiographic changes, such as LVD, LVH, and global hypokinesia, were observed in greater number in hypertensive group com-
pared to normotensive group (P < 0.05). On regression analysis adjusted for age and gender, we found that hypertension and anemia (<10 g/dL) 
were associated with LVH. Further, hypertension and anemia (Hb < 10 g/dL) were associated with LVD. Similarly, anemia (Hb < 10 g/dL) was 
associated with global hypokinesia and valvular heart disease. LVD was associated with death in our study. 
Conclusion: Echocardiography is a noninvasive diagnostic test which detects early changes in cardiac parameters. All ESRD patients with hyper-
tension and anemia at the time of initiation of renal replacement therapy must undergo echocardiography screening.
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Introduction
Patients with chronic kidney disease (CKD) have a tre-
mendous burden of cardiovascular disease (CVD), and 
patients with end-stage renal disease (ESRD) are at a greater 
risk of CVD and death (1,2,3). CKD is a risk factor for 
cardiovascular events, and the risk of events increases as 
CKD progresses to ESRD. Association of CKD with CVD 
is commonly explained by a typical clustering of several car-
diovascular risk factors, including traditional and nontradi-
tional CKD-related factors (2,3,4). Anemia and hypertension 
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are most consistently associated with cardiac failure, a pre-le-
thal occurrence that leads to two-thirds of deaths in all 
patients on dialysis (5). The risk of cardiovascular mortal-
ity is 10- to 20-fold higher than in age- and gender-matched 
control subjects (2,5). One of the major structural cardiac 
abnormalities in patients with CKD is left ventricular hyper-
trophy (LVH), which is associated with increased risk for 
cardiac ischemia, congestive heart failure as well as a very 
strong independent predictor of cardiovascular mortality 
(1,6,7). LVH is the most common geometric abnormality 
in CKD and independent prognostic predictor, especially in 
patients on dialysis (8). Left ventricular dysfunction (LVD) 
on start of hemodialysis is a stratifying risk of CVD and an 
all-cause mortality in ESRD (6,9). It is strongly associated 
with cardiac failure and as one of the independent predictors 
of cardiovascular death. Echocardiography is a simple and 
established method of evaluating cardiac functions, assessing 
left ventricle geometry, and systolic and diastolic functions.
Materials and Methods
In this prospective observational study conducted in a ter-
tiary care teaching hospital over a period of 1 year, the 
included patients were incident dialysis patients, and none 
of the patient was on erythropoietin. All the patients were 
aged >18 years. Patients with ESRD already on maintenance 
dialysis were not included in this study. Patient data such as 
demographic details, comorbidities, laboratory values, echo-
cardiographic changes, management, and outcome were 
recorded. Echocardiography (two-dimensional and M-mode) 
was done in all patients. A total of 245 patients were included 
in the study. Data analysis was performed using statistical 
software SPSS (Version 20.0). Descriptive statistics were used 
for the analysis. Statistical tests were two-tailed, and P < 0.05 
was considered to show a statistical difference. Chi-square 
test for association was performed between different treat-
ment modalities used and the patient outcomes.
Results
Out of the included 245 patients, 165 (67.3%) were males and 
80 (32.6%) females. The mean age of the patients was 49.7 
years, and the mean serum creatinine was 7.7 mg/dL. The 
majority of patients were in the age group of 41–50 years, 
as shown in Table 1. Hypertension was found in 199 (81%), 
diabetes in 70 (28.5%), coronary heart disease (CHD) in 18 
(7.3%), and anemia in 193 (78.7%) patients. Etiology of the 
CKD was presumed. Chronic interstitial nephritis (CIN) 
was established in 189 (77.1%), chronic glomerulonephritis 
(CGN) in 26 (10.6%), diabetic kidney disease in 23 (9.38%), 
and polycystic kidney disease in 7 (2.8%) patients. LVH was 
observed in 188 (76.7%), mild LVD in 25.7%, moderate LVD 
in 23.67%, severe LVD in 8.5%, global hypokinesia in 33.8%, 
Table 1: Demographic details of patients
Mean age 49.7
Mean serum creatinine 7.7
Males 165 (67%)
Females 80
Table 2: Echocardiographic changes. 
Echocardiographic Changes Number of Patients 
N (%)
LVH 188 (76.7%)
Mild LVD 63 (25.7%)
Moderate LVD 58 (23.67%)
Severe LVD 21 (8.5%)
Global hypokinesia 83 (33.8%)
RWMA 11 (4.4%)
Valvular heart disease 65 (26.5%)
Pericardial effusion 4 (1.6%)
RWMA: regional wall motion abnormalities; LVD: left 
ventricular dysfunction; LVH: left ventricular hypertrophy.
valvular heart disease in 26.5%, regional wall motion abnor-
mality (RWMA) in 4.4%, and pericardial effusion in 1.6% 
patients (Table 2). Echocardiographic changes, such as LVD, 
left ventricular hypertrophy (LVH), and global hypokinesia, 
were found in greater number in hypertensive group com-
pared to normotensive group (P < 0.05) (Table 3). Patients 
with hemoglobin (Hb) < 10 gm/dL had echocardiographic 
changes such as LVH in 82%, LVD in 66%, global hypo-
kinesia in 49%, and valvular heart disease in 30% patients, 
with statistically significant P < 0.05, compared with ane-
mic patients with Hb >10 gm/dL (Table 4). Patients were 
further analyzed on the basis of ejection fraction (EF), and 
demographic details, comorbidities, and echocardiographic 
changes and outcomes were also studied. In reduced EF 
group, 68.7% were females, 64% had hypertension, 75.8% 
had LVH, and RWMA was found in 81.8% patients. Among 
patients who died, 92.3% had reduced EF (Table 5). Patients 
with LVD and global hypokinesia had higher mortality com-
pared with those who had normal left ventricular function 
with a statistically significant P < 0.05 (Table 6). On regres-
sion analysis adjusted for age and gender, we found that 
hypertension and anemia (Hb < 10 g/dL) was associated with 
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Table 3: Echocardiographic changes compared in normotensive and hypertensive patients.
Hypertensive (N = 199) Normotensive (N = 46) P-value 
LVD 128 14 0.00032
LVH 174 14 <0.001
Global hypokinesia 74 9 0.02
RWMA 10 1 0.47
Valvular heart disease 59 6 0.025
Pericardial effusion 2 2 0.16
RWMA: regional wall motion abnormalities; LVD: left ventricular dysfunction; LVH: left ventricular hypertrophy.
Table 4: Echo changes compared with hemoglobin values.
Hb < 10 gm/dL (N = 193) Hb > 10 gm/dL (N = 52) P-value
LVH 159 (82%) 29 (15%) 0.0003
LVD 128 (66%) 14 (7.2%) <0.0001
Global hypokinesia 79 (49%) 4 (2%) 0.000004
RWMA 10 (5.1%) 1 (0.5%) 0.47
Valvular heart disease 58 (30%) 7 (3.6%) 0.02
Pericardial effusion 3 (1.5%) 1 (0.5%) 1
RWMA: regional wall motion abnormalities; LVD: left ventricular dysfunction; LVH: left ventricular hypertrophy.
Table 5: Comparison of groups with preserved and reduced ejection fraction
Column 1 Preserved EF (103) Reduced EF (n = 142) P value
Male 76 (46.6%) 87 (53.7%)
Female 26 (32.5%) 55 (68.7%)
HTN 71 (35.6%) 128 (64%) 0.00003
DM 29 (41.4%) 41 (56.9%) 1
CAD 3 (16.6%) 15 (83%) 0.02
LVH 43 (24%) 135 (75.8%) 2.6
RWMA 2 (18%) 9 (81.8%) 0.1
Valvular heart disease 14 (22.9%) 47 (77%) 0.00052
PE 2 (40%) 3 (60%) 1
Global hypokinesia 13 (13.5%) 83 (86.4%) 2.3
Hb < 10 gm/dL 65 (33.6%) 128 (66.3%) 3.7
Death 2 (7.6%) 24 (92.3%) 0.00021
HTN: Hypertension; DM : Diabetes Mellitus; CAD: Coronary artery disease; LVH: Left Ventricular Hypertrophy;  
PE: Pericardial Effusion; Hb: Haemoglobin
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Hb < 10 gm/dL 23 0.3
LVH 23 0.2
LVD 24 0.002
Global hypokinesia 19 0.0001
RWMA 3 0.1
Valvular heart disease 9 0.3
Pericardial effusion 1 0.3
RWMA: regional wall motion abnormalities; LVD: left 
ventricular dysfunction; LVH: left ventricular hypertrophy.
Table 7: Comparison with other studies.
N LVH LVD 
Overall HTN Hb (<10 gm/dL) 
Present study 245 76.7% 87% 82% 57%
Foley et al. (7) 433 75%
Bansal et al. (1) 190 79% 48%
Laddha et al. (10) 70 74% 74% 82% 23% 
Zoccali et al. (9) 71% 46%
Yamada et al. (6) 1254 13%, EF < 35 predicts poor outcome 
Datta et al. (11) 230 96% 89% 51% 
LVD: left ventricular dysfunction; LVH: left ventricular hypertrophy; EF: ejection fraction; HTN: Hypertension
LVH with odds ratio (OR) = 0.06 and 0.29 (P < 0.001 and 
P  = 0.003), respectively. Further, hypertension and anemia 
(Hb < 10 g/dL) were associated with LVD with OR = 3.36 
and 5.04 (P = 0.001 and P < 0.001), respectively. Similarly, 
anemia (Hb < 10 g/dL) was associated with global hypokine-
sia, OR = 8.44 (P < 0.001) and valvular heart disease, OR = 
4.02 (P = 0.006). LVD was associated with mortality with 
OR = 16.9 (P = 0.001).
Discussion
Cardiovascular disease is very common in patients with 
CKD, and is by far the leading cause of morbidity and mor-
tality in end-stage renal disease. We observed that majority 
of the patients were aged 41–50 years, with the mean age of 
49.7 years, similar to the findings of Singh et al. (5) (Table 7). 
In our study, male population (67%) was predominant, sim-
ilar to Singh et al. (5) and Foley et al. (7). Hypertension was 
found in 81.2% patients, correlating with other studies (6,8). 
We observed significant echocardiographic changes in hyper-
tensive group compared to normotensive group. LVH was 
examined in 76% patients, as observed by Laddha et al., who 
observed LVH in 74% patients in their study (10). In a study 
conducted by Zoccali et al., LVH was found in 77% patients 
(9). Similar observations were made by Singh et al. (5). In 
anemic patients (with Hb < 10 gm/dL), echocardiogarphic 
changes were observed correlating with other studies. In ane-
mic patients, LVH was found in 82% and LVD in 66% cases. 
It was comparable with the observations made by Singh et al. 
(5), Parfrey et al. (8), and Datta et al. (11). Patients with 
reduced EF had higher risk of valvular heart disease and 
significant mortality, similar to the observations made by 
Yamada et al. (6). Mortality occurred in 26 (10.6%) patients; 
among these, Hb < 10 gm/dL was found in 23 (88.4%), LVH 
in 23 (88.4%), LVD in 24 (92%), and global hypokinesia in 
19 (73%) patients, correlating with the studies carried out by 
Yamada et al. (6) and Zoccali et al. (9).
Limitations
This was a 1-year study and no further follow-up took place. 
Conclusion
Echocardiohraphy is a noninvasive diagnostic test to 
detect early changes in cardiac parameters. All ESRD 
patients with hypertension and anemia at the time of initi-
ation of renal replacement therapy (RRT) should undergo 
 echocardiography screening.
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